Co-Diagnostics shareholders increased the equity incentive plan reserve by 2,000,000 shares to 2,223,333, approved warrants for 3,404,724 shares at $1.56, and authorized reverse stock splits of not less than 1-for-2 and up to 1-for-750.
CODX · Co-Diagnostics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued. These uncertainties create substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Co-Diagnostics reported $0.7 million cash and cash equivalents at September 30, 2026, versus total current liabilities of $2.5 million, and said additional capital is required, creating substantial doubt about its ability to continue as a going concern.
Co-Diagnostics reported third-quarter revenue of $0.3 million versus $0.1 million in the third quarter of 2025, but net loss was $6.3 million versus $5.9 million. Cash and cash equivalents totaled $0.7 million as of September 30, 2026.
Co-Diagnostics registered up to 39,594,495 common shares for J.J. Astor & Co.’s resale, including conversion shares and 600,000 commitment shares tied to convertible notes. Astor funded $2.1 million initially, with another $1.0 million available; Co-Diagnostics receives no resale proceeds.
Co-Diagnostics, Inc. will ask shareholders on November 13, 2026 to authorize reverse stock splits of not less than 1-for-2 and up to 1-for-750, approve potential exercise of warrants for 3,404,724 shares at $1.56 per share, and address director elections and equity compensation.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Co-Diagnostics reported a $6.3M net loss on $166K of Q2 revenue while submitting its FDA 510(k) and CLIA waiver application for the Co-Dx PCR Flu A/B & RSV test, advancing TB clinical work in India, and completing a proof-of-concept Ebola assay. Cash fell to $3.6M from $11.9M at year-end 2025, prompting the company to flag potential dilutive financings to support commercialization.
- + Submitted 510(k) and CLIA waiver application for the Flu A/B & RSV test after completing clinical studies with 1,400+ patients and 27 analytical studies. new
- + Reduced net loss to $6.3M from $7.7M and cut operating expenses to $6.3M from $8.2M year-over-year. new
- + Completed proof-of-concept Ebola assay on the Co-Dx PCR Pro and supplied Bundibugyo test kits for evaluation in India. new
- − Revenue remains minimal at $166K, with gross profit declining to $121K from $131K year-over-year. new
- − Cash and cash equivalents declined to $3.6M from $11.9M at year-end 2025, and management flagged potential dilutive financings ahead. new
- − Management expects continued operating losses in the near term with commercialization still pending. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 5.8M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CODX
this stock
Co-Diagnostics, Inc.
|
$2.72M | — | -84.1% | — | 9.3% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 34
Co-Diagnostics shareholders increased the equity incentive plan reserve by 2,000,000 shares to 2,223,333, approved warrants for 3,404,724 shares at $1.56, and authorized reverse stock splits of not less than 1-for-2 and up to 1-for-750.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CODX | +0.7% | -60.5% | -97.2% | -29.5% | -94.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.9% | -59.3% | -97.7% | -29.3% | -105.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.